Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kosan Biosciences has announced that the tanespimycin in myeloma evaluation or TIME-1 pivotal Phase III trial for tanespimycin as a potential treatment for multiple myeloma is open for enrollment.
Subscribe to our email newsletter
The TIME registration program is designed to include two trials, a pivotal Phase III trial (TIME-1) and a smaller supportive trial. The TIME-1 trial is proceeding on track and remains the foundation of the company’s registration strategy. The TIME-2 trial, recently opened for patients who have failed numerous (at least three) prior myeloma therapies, will be closed and replaced with an alternative supportive trial. TIME-2 had been designed to support TIME-1 for full approval as well as to provide a potential strategy for pursuing accelerated approval.
TIME-1 is an open-label, randomized, multi-center, international Phase III trial comparing tanespimycin in combination with bortezomib (Velcade) with bortezomib alone in patients following a single prior course of treatment (first-relapse). The trial is designed with a primary endpoint of progression-free survival (PFS), and there are several predefined secondary endpoints. TIME-1 is powered to show a 2.75 month PFS benefit in the tanespimycin plus bortezomib group compared to the bortezomib alone group.